Skip Navigation


European Heart Journal Advance Access originally published online on June 16, 2006
European Heart Journal 2006 27(14):1635-1636; doi:10.1093/eurheartj/ehl090
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
27/14/1635    most recent
ehl090v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Bhatt, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bhatt, D. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

NSAIDS and the risk of myocardial infarction: do they help or harm?

Deepak L. Bhatt*

Cleveland Clinic Cardiovascular Coordinating Center, Department of Cardiovascular Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk F25, Cleveland, OH 44195, USA

* Corresponding author. Tel: +1 216 445 4042; fax: +1 216 445 8531. E-mail address: bhattd@ccf.org

This editorial refers to ‘NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case–control study from Finland’{dagger} by A. Helin-Salmivaara et al., on page 1657

The first 10% of the full text of this article appears below.

Non-steroidal anti-inflammatory drugs (NSAIDS) are commonly used for pain relief and appear to work primarily by inhibiting cyclooxygenase (COX) enzymes. Aspirin and other traditional NSAIDS non-selectively inhibit both COX-1 and COX-2 isoforms. In contradistinction, the various coxibs more selectively inhibit COX-2, with differing degrees of specificity. Aspirin has unequivocally been demonstrated to reduce myocardial infarction (MI) in patients with established coronary artery disease.1 The predominant mechanism by which aspirin provides cardiovascular protection is believed to be via irreversible inhibition of COX-1-mediated platelet aggregation. Prior reports in the literature regarding cardiovascular effects of NSAIDS have been conflicting, whereas the cardiovascular effect of COX-2 inhibitors has been nothing but controversial.

The important report by Helin-Salmivaara et al. in this issue of the European Heart Journal is the largest population-based matched case–control study of NSAIDS performed to date.2 A total . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case–control study from Finland
Arja Helin-Salmivaara, Arja Virtanen, Risto Vesalainen, Juha M. Grönroos, Timo Klaukka, Juhana E. Idänpään-Heikkilä, and Risto Huupponen
EHJ 2006 27: 1657-1663. [Abstract] [Full Text]  



This article has been cited by other articles:


Home page
 Health Aff (Millwood)Home page
R. M. Califf, R. A. Harrington, L. K. Madre, E. D. Peterson, D. Roth, and K. A. Schulman
Curbing The Cardiovascular Disease Epidemic: Aligning Industry, Government, Payers, And Academics
Health Aff., January 1, 2007; 26(1): 62 - 74.
[Abstract] [Full Text] [PDF]